A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis - Trial NCT06143878
Access comprehensive clinical trial information for NCT06143878 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Research & Development, LLC and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 750 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Janssen Research & Development, LLC
Timeline & Enrollment
Phase 3
Feb 09, 2024
Oct 25, 2027
Primary Outcome
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (=) 2-Grade Improvement From Baseline to Week 16,JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with
 moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06143878
Non-Device Trial